资讯

Pharmaceutical Technology1 小时
Biogen’s Q1 revenue soars past estimates as rare disease pivot pays off
Biogen’s CEO Chris Vibacher said ‘a new Biogen’ is emerging following the end of its multiple sclerosis treatments heyday.